Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes Export

@article{citeulike:4096391, abstract = {Glucagon is secreted from the {alpha}-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM. 10.1152/ajpendo.90887.2008}, author = {Ali, Safina and Drucker, Daniel J.}, citeulike-article-id = {4096391}, citeulike-linkout-0 = {http://dx.doi.org/10.1152/ajpendo.90887.2008}, citeulike-linkout-1 = {http://ajpendo.physiology.org/cgi/content/abstract/296/3/E415?etoc}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/19116373}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=19116373}, day = {1}, doi = {10.1152/ajpendo.90887.2008}, journal = {Am J Physiol Endocrinol Metab}, keywords = {diabetes, glp-1, glycemiapp, physiology}, month = {March}, number = {3}, pages = {E415--421}, posted-at = {2009-02-25 01:39:03}, priority = {2}, title = {Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes}, url = {http://dx.doi.org/10.1152/ajpendo.90887.2008}, volume = {296}, year = {2009} }

TY - JOUR ID - citeulike:4096391 L3 - citeulike-article-id:4096391 N2 - Glucagon is secreted from the {alpha}-cells of the pancreatic islets and regulates glucose homeostasis through modulation of hepatic glucose production. As elevated glucagon levels contribute to the pathophysiology of hyperglycemia in subjects with type 2 diabetes, reduction of glucagon receptor gene (Gcgr) activity represents a potential target for the treatment of T2DM. Herein, we review current concepts of glucagon action in hepatic and extrahepatic tissues and evaluate the therapeutic potential, mechanisms of action, and safety of reducing Gcgr signaling for the treatment of T2DM. 10.1152/ajpendo.90887.2008 IS - 3 JF - Am J Physiol Endocrinol Metab EP - 421 TI - Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes VL - 296 SP - E415 KW - diabetes KW - glp-1 KW - glycemiapp KW - physiology AU - Ali, Safina AU - Drucker, Daniel PY - 2009/03/01/ UR - http://dx.doi.org/10.1152/ajpendo.90887.2008 ER -